Overview
IGM Biosciences, Inc. is a biotechnology firm based in the United States, focusing on the development of novel immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company leverages its proprietary IgM technology platform to create and develop engineered monoclonal antibodies intended to offer improved therapeutic benefits over existing IgG antibody technologies. One of its significant projects includes the development of IGM-2323, a bispecific IgM antibody targeting CD20 x CD3, which is in clinical trials as a potential treatment for B-cell non-Hodgkin's lymphomas. IGM Biosciences continues to innovate in the antibody therapeutic space, advancing a pipeline that also addresses other serious unmet medical needs.
Basic Stats
The share price of IGM Biosciences, Inc. as of August 13, 2025 is $1.27 / share.
The Factor Analysis chart (below right) shows a view of IGM Biosciences, Inc. from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | |
| EV | |
| Shares Out. | |
| Earnings Date | |
| EPS (TTM) | |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | |
| Short Shares Avail. | 0.00 MM |
| Short Interest | 0.00 MM |
| Short Float | |
| Days to Cover | |
| Risk Free Rate | 4.22 % |
| Price Change (1 yr) | |
| Volatility (1 yr) | 1.09 |
| Beta | 1.37 |
| Sharpe Ratio (1 yr) | |
| Sortino Ratio (1 yr) |
| PE Ratio | |
| Price/Book | |
| Price/TBV | |
| Book/Market | |
| EBIT/EV | |
| EBIT(3yr avg)/EV | |
| ROA | |
| ROE | |
| ROIC | |
| CROIC | |
| OCROIC | |
| Implied Volatility | |
| Put/Call OI Ratio |
| Growth | |
| Profitability | |
| Quality Score | |
| Value Score | |
| Momentum Score | |
| Stability (Low Vol) Score | |
| Analyst Sentiment | |
| Fund Sentiment | |
| Insider Sentiment | |
| Officer Sentiment | |
| Dividend Score | |
| QVM Score | |
| Piotroski F-SCORE |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for IGM Biosciences, Inc. is $1.28. The forecasts range from a low of $0.76 to a high of $2.10. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for IGM Biosciences, Inc.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2022-11-04 | RBC Capital | Sector Perform | Maintains | |
| 2022-10-17 | JP Morgan | Neutral | Initiate | |
| 2022-08-29 | B of A Securities | Buy | Initiate | |
| 2022-08-23 | Truist Securities | Buy | Maintains | |
| 2022-06-01 | Baird | Outperform | Maintains | |
| 2022-05-17 | HC Wainwright & Co. | Buy | Maintains | |
| 2022-04-04 | Baird | Outperform | Maintains | |
| 2022-03-31 | HC Wainwright & Co. | Buy | Maintains | |
| 2022-03-30 | Truist Securities | Buy | Maintains | |
| 2022-03-30 | Morgan Stanley | Equal-Weight | Maintains | |
| 2021-12-16 | HC Wainwright & Co. | Buy | Maintains | |
| 2021-12-14 | Morgan Stanley | Overweight | Equal-Weight | Downgrade |
| 2021-12-13 | Stifel | Buy | Maintains | |
| 2021-12-13 | RBC Capital | Outperform | Sector Perform | Downgrade |
| 2021-12-13 | Jefferies | Buy | Maintains | |
| 2021-11-05 | Wedbush | Neutral | Outperform | Upgrade |
| 2021-11-05 | RBC Capital | Outperform | Maintains | |
| 2021-08-26 | Morgan Stanley | Overweight | Initiate | |
| 2021-08-16 | Wedbush | Neutral | Maintains | |
| 2021-01-29 | RBC Capital | Outperform | Initiate | |
| 2021-01-19 | HC Wainwright & Co. | Buy | Maintains | |
| 2020-12-22 | Wedbush | Outperform | Neutral | Downgrade |
| 2020-07-17 | Baird | Outperform | Initiate | |
| 2020-07-01 | HC Wainwright & Co. | Buy | Initiate | |
| 2020-06-30 | Stifel | Buy | Maintains | |
| 2020-05-28 | SunTrust Robinson Humphrey | Buy | Initiate | |
| 2020-05-08 | Stifel | Buy | Maintains | |
| 2020-04-22 | Wedbush | Outperform | Initiate | |
| 2020-01-06 | PiperJaffray | Overweight | Maintains | |
| 2019-10-14 | Stifel Nicolaus | Buy | Initiate | |
| 2019-10-14 | Piper Jaffray | Overweight | Initiate | |
| 2019-10-14 | Guggenheim | Buy | Initiate | |
| 2022-11-07 | HC Wainwright & Co. | Buy | Maintains | |
| 2023-04-04 | Truist Securities | Buy | Maintains | |
| 2023-03-31 | RBC Capital | Sector Perform | Maintains | |
| 2023-05-15 | RBC Capital | Sector Perform | Sector Perform | Maintains |
| 2023-05-15 | Wedbush | Outperform | Outperform | Maintains |
| 2023-04-03 | Morgan Stanley | Equal-Weight | Maintains | |
| 2023-04-03 | JP Morgan | Neutral | Maintains | |
| 2023-04-03 | HC Wainwright & Co. | Buy | Maintains | |
| 2023-05-16 | JP Morgan | Neutral | Neutral | Maintains |
| 2023-06-05 | Wedbush | Outperform | Outperform | Reiterate |
| 2023-06-06 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2023-12-07 | HC Wainwright & Co. | Buy | Neutral | Downgrade |
| 2023-11-15 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2023-11-15 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2023-08-17 | RBC Capital | Sector Perform | Sector Perform | Reiterate |
| 2023-09-06 | Truist Securities | Buy | Buy | Reiterate |
| 2023-11-14 | RBC Capital | Sector Perform | Sector Perform | Maintains |
| 2023-11-14 | Stifel | Buy | Buy | Maintains |
| 2023-08-07 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2023-08-07 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2023-08-07 | Needham | Buy | Hold | Downgrade |
| 2023-12-06 | RBC Capital | Sector Perform | Sector Perform | Maintains |
| 2023-12-15 | B of A Securities | Buy | Neutral | Downgrade |
| 2024-03-08 | Wedbush | Outperform | Outperform | Reiterate |
| 2024-03-08 | RBC Capital | Outperform | Outperform | Reiterate |
| 2024-04-18 | HC Wainwright & Co. | Neutral | Neutral | Reiterate |
| 2024-02-09 | RBC Capital | Sector Perform | Outperform | Upgrade |
| 2024-05-09 | Wedbush | Outperform | Outperform | Reiterate |
| 2024-05-24 | HC Wainwright & Co. | Neutral | Neutral | Reiterate |
| 2024-03-12 | HC Wainwright & Co. | Neutral | Neutral | Maintains |
| 2024-08-15 | Wedbush | Outperform | Outperform | Maintains |
| 2024-08-15 | RBC Capital | Outperform | Outperform | Reiterate |
| 2024-08-15 | JP Morgan | Neutral | Neutral | Maintains |
| 2024-08-23 | Truist Securities | Buy | Buy | Maintains |
| 2025-01-10 | BMO Capital | Outperform | Market Perform | Downgrade |
| 2025-01-10 | RBC Capital | Outperform | Sector Perform | Downgrade |
| 2025-01-10 | Stifel | Buy | Hold | Downgrade |
| 2025-01-10 | Truist Securities | Hold | Hold | Maintains |
| 2025-01-10 | Jefferies | Buy | Hold | Downgrade |
| 2024-11-11 | Stifel | Buy | Buy | Maintains |
| 2024-09-05 | HC Wainwright & Co. | Neutral | Neutral | Maintains |
| 2024-12-06 | BMO Capital | Outperform | Initiate | |
| 2024-10-18 | RBC Capital | Outperform | Outperform | Maintains |
| 2024-10-01 | Guggenheim | Buy | Buy | Maintains |
| 2024-10-01 | Wedbush | Outperform | Outperform | Maintains |
| 2024-10-01 | RBC Capital | Outperform | Outperform | Maintains |
| 2024-10-01 | Truist Securities | Buy | Hold | Downgrade |
| 2024-10-01 | JP Morgan | Neutral | Underweight | Downgrade |
| 2025-01-13 | JP Morgan | Underweight | Neutral | Upgrade |
| 2025-06-11 | Truist Securities | Hold | Hold | Maintains |
